Phase 3 N=188 Effectiveness of Ultrafiltration in Treating People With Acute Decompensated Heart Failure and Cardiorenal Syndrome (The CARRESS Study)
Heart Failure
Primary: Change in Serum Creatinine — -0.04; 0.23 mg/dL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=80 The Effect in Renal Function on Patients With Type 1 Cardiorenal Syndrome Treated With Two Strategies of Furosemide.
Cardiorenal Syndrome
Primary: Number of Participants With Renal Function Recovery Defined as a Return to Individual Baseline Serum Creatinine Values — 8; 5 Participants
N/A N=21 The Aortix CRS Pilot Study
Heart Failure; With Decompensation · Cardiorenal Syndrome · Cardio-Renal Syndrome
Primary: Serious Adverse Events — 18 Events
Early Phase 1 N=46 Assessment of Renal Function by Multiparametric MRI
Renal Impairment
Primary: T1 Time — 1500 ms
N/A N=146 Prevalence of Renal Artery Stenosis in Patients Referred for Cardiac Catheterization
Renal Artery Stenosis
Primary: Prevalence of Renal Artery Stenosis (RAS)
Phase 2 N=33 CR Aim #2 - AT1 Receptor Blockade & ACE Inhibition Effect on Humoral Function
Cardiorenal Syndrome (CRS)
Primary: Change in Glomerular Filtration Rate — -5; 1.00 ml/min/1.73 m2 — p=0.26
N/A N=73 Kidney Response to Sepsis Affects Angiogenic Balance and Likelihood of CCI and PICS
Sepsis
Primary: Delta Curve Between Calculated GFR and GFR Measured by Iohexol at Baseline — 91.5; 88.3; 93.6; 90.0 ml/min/1.73m2 — p=<0.05
N/A N=15,724 Intensive Monitoring of Renal Function
Intensive Monitoring of Renal Function · Acute Kidney Injury
Primary: Detection of Acute Kidney Injury (AKI) — 1.22; 1.22; 1.11; 1.11 Odds Ratio
Phase 3 N=57 Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome
Type 2 Diabetes Mellitus · Chronic Kidney Disease · Left Ventricular Diastolic Dysfunction
Primary: Galectin-3 — 9570.91; 9266.7; 9539.21; 8098.78 pg/ml
Phase 4 N=120 Paricalcitol Versus Calcitriol for the Management of Renocardiac Syndrome in Renal Transplant Patients
Cardiorenal Syndrome · Chronic Allograft Nephropathy
Primary: CAD (Chronic Allograft Dysfunction) Degree — 1.24; 1.22; 1.43; 1.68 Scores on a Banff scale — p=<0.05
N/A N=6,295 Chronic Kidney Disease Clinical Decision Support
Chronic Kidney Diseases · Hypertension · Diabetes
Primary: Number of Participants With CKD Diagnosis — 417; 389 Participants — p=.21
N/A N=18 Renal Perfusion, Filtration and Oxygenation During Cardiopulmonary Bypass (CPB)
Complication of Extracorporeal Circulation · Renal Impairment
Primary: Renal Blood Flow (RBF) — 554; 524; 564; 558 ml per minute per 1.73 m2 body surface — p=0.638
Phase 2 N=92 Prevention of Acute Kidney Injury in Cardiac Surgery Patients
Kidney Injury
Primary: Number of Participants With Acute Kidney Injury — 20; 14 participants
N/A N=781 Chronic Kidney Disease (CKD) Guideline Adherence - A Quality Improvement Study
Chronic Renal Insufficiency
Primary: PTH (Parathyroid Hormone) Adherence — 0.23; 0.28 probability of having a PTH measured — p=0.04
Phase 2 N=20 Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Systolic Cardiomyopathy (Aim2)
Cardiomyopathy · Renal Impairment
Primary: Change in Urinary Sodium Excretion — 29.5; 25.1 MEq/min — p=0.8
Phase 3 N=294 RenalGuard System and Contrast Media
Chronic Kidney Disease
Primary: Number of Participants With Contrast-induced Acute Kidney Injury — 146; 146 participants
N/A N=20 Metabolic Acidosis and Vascular Function in Patients With Chronic Kidney Disease
Metabolic Acidosis · Chronic Kidney Disease
Primary: Change in Brachial Artery Flow Mediated Dilation (FMD) — 1.1; -0.7 absolute change in percent FMD
N/A N=1,113 Renal Replacement Therapy and In-Hospital Mortality Incidence in Cardiac Surgery Associated Acute Kidney Injury
Acute Kidney Injury
Primary: Mortality — 96; 34 Participants — p=<0.0001
Phase 2 N=22 Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Diastolic Cardiomyopathy (Aim3)
Cardiomyopathy · Renal Impairment
Primary: Change in Urinary Sodium Excretion — 74.43; 29.11 MEq/min — p=0.04
Phase 2 N=60 Metformin in Kidney Disease
Chronic Kidney Disease · Cardiovascular Disease · Metabolic Syndrome
Primary: Change is Leptin to Adiponectin Ratio (LAR) — 2.2; 1.3; 1.3; 1.4 ng/micrograms
Phase 2 N=90 Low Dose Continuous Furosemide Effect on Cardiac Surgery Patients With Kidney Dysfunction
Chronic Kidney Disease · Cardiac Disease
Primary: Glomerular Filtration Rate at Baseline — 56; 67 mL/mnt/1.73 m^2
Phase 2 N=15 Inflammation in Chronic Kidney Disease and Cardiovascular Disease - The Role of Genetics and Interleukin-1 Receptor Antagonist (IL-1ra)
Chronic Kidney Disease · Cardiovascular Disease
Primary: Change in the Concentration of High Sensitivity C-Reactive Protein (hsCRP) From Baseline to 12 Weeks — -2.6; 0.8 mg/dl — p=0.03
N/A N=35 Safety Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Renal Failure
Acute Renal Failure
Primary: 60 Day Mortality — 11 Participants
Phase 4 N=89 Assessment of Biomarkers and Cardiorenal Syndrome in Acute Decompensated Heart Failure With Vasodilator Therapy
Acute Decompensated Heart Failure
Primary: Renal Function by Serum Creatinine — 1.3; 1.3; 1.3; 1.4 mg/dL
N/A N=10,252 IMPROVE AKI Cluster-Randomized Trial
Acute Kidney Injury
Primary: Acute Kidney Injury — 110; 190; 122; 88 Participants
Phase 2 N=30 Fluid Chloride and AKI in Cardiopulmonary Bypass
Acute Kidney Injury
Primary: Change in [TIMP2]*[IGFBP7] Biomarker — 0.015; 0.009 (ng/mL)^2/1000
N/A N=14 Chronic Kidney Disease Among Frail Elderly
Chronic Kidney Disease
Primary: Mortality — 0; 0 percentage of mortality
Phase 4 N=107 Mechanisms for the Effect of Acetylcysteine on Renal Function After Exposure to Radiographic Contrast Material
Radiocontrast-induced Nephropathy
Primary: Changes in Renal Blood Flow — 9590.8; 5105.4; 8529.4; 5228.4 h.mL/min
Phase 2 N=101 Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease
Pre-hypertension
Primary: Change in Disease Score (DS) Among the Treatment Groups — -2.48; -2.29; -2.38; -0.96 Overall Rasmussen Disease Score Change
N/A N=1,529 Advance Cardiac Resynchronization Therapy (CRT) Registry
Heart Failure
Primary: Number of CRT Non-responders Using 1) Clinical Composite Score (CCS) and 2) Site-specific Criteria for Determining CRT Response — 1061; 900 Participants